|Bid||22.30 x 900|
|Ask||27.60 x 800|
|Day's Range||22.70 - 23.15|
|52 Week Range||18.58 - 67.36|
|Beta (3Y Monthly)||0.98|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||65.60|
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors,.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...
The studies are ongoing, and the company anticipates reporting interim results from both studies during Q2 of 2019. “Completing patient enrollment in both of our first Phase 2 studies marks an important milestone for our ongoing HBV clinical program and brings the potential of a cure closer to the millions of patients suffering from this chronic disease,” said Derek Small, President and Chief Executive Officer. “The data from these studies will serve to inform the timelines of the HBV cure program as well as the design of future registrational studies.
Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. NASDAQ and Russell 2000 indices are already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in the first half of […]
Amphastar Pharmaceuticals (AMPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Derek Small became the CEO of Assembly Biosciences Inc (NASDAQ:ASMB) in 2015. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth that Read More...
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 14.71% and 33.40%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Carmel, Indiana-based company said it had a loss of 87 cents. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assembly Biosciences Inc (NASDAQ: ASMB ) shares have shed over one-fourth of their value since late September, creating an opportunity to buy the dip, B. Riley FBR said Monday. The Analyst Analyst Madhu ...
Every investor in Assembly Biosciences Inc (NASDAQ:ASMB) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often Read More...
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of -44.44% and -2.49%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Carmel, Indiana-based company said it had a loss of $1.30 per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...